Where Oncologic and Surgical Complication Scoring Systems Collide: Time for a New Consensus for CRS/HIPEC by Eshmuminov, Dilmurodjon
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Where Oncologic and Surgical Complication Scoring Systems Collide: Time
for a New Consensus for CRS/HIPEC
Eshmuminov, Dilmurodjon
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-135372
Originally published at:
Eshmuminov, Dilmurodjon. Where Oncologic and Surgical Complication Scoring Systems Collide: Time
for a New Consensus for CRS/HIPEC. 2016, University of Zurich, Faculty of Medicine.
    
Universitätsspital Zürich 
Klinik für Viszeral- und Transplantationschirurgie 
Direktor: Prof. Dr. med. Pierre-Alain Clavien PhD 
 
 
 
Arbeit unter Leitung von Dr. med. Dr. sc. nat. Kuno Lehmann 
 
 
 
 
 
 
 
 
Where Oncologic and Surgical Complication Scoring 
Systems Collide: Time for a New Consensus for 
CRS/HIPEC 
 
 
  
 
 
 
 
INAUGURAL-DISSERTATION 
zur Erlangung der Doktorwürde der Humanmedizin  
der Medizinischen Fakultät 
der Universität Zürich 
 
 
 
 
 
 
vorgelegt von 
Dilmurodjon Eshmuminov 
 
 
 
  
 
 
Genehmigt auf Antrag von Prof. Dr. med. P. A. Clavien 
Zürich 2016 
 
Page 2 of 12 
Publikationshinweis 
 
 
Titel der Publikation: Where Oncologic and Surgical Complication Scoring 
Systems Collide: Time for a New Consensus for CRS/HIPEC 
 
 
 
Publiziert online am:  15 December 2015  
 
 
Journal:  World Journal of Surgery  
  http://www.ncbi.nlm.nih.gov/pubmed/26669784  
  
Page 3 of 12 
Publication 
 
  
Page 4 of 12 
Acknowledgements 
 
This study and thesis was conducted under guidance of Prof. Clavien, whom I am 
very grateful.  
I would like to express my sincere gratitude to Dr. Lehmann for his excellent 
support and guidance. 
Further I would like to express my thanks Dr. Slankamenac for helping with the 
statistical analysis and interpretation of results. 
  
Page 5 of 12 
Begleittext zur Publikation (equal contribution) 
 
Von Dilmurodjon Eshmuminov    
 
 
Background 
Peritoneal carcinomatosis is considered as a terminal stage of many gastrointestinal 
tumors.1-3 Systemic Chemotherapy improves outcomes but does very rarely offer long-term 
survival.1, 4  In the last three decades, cytoreductive surgery (CRS) combined with hyperthermic 
intraperitoneal chemotherapy (HIPEC) has provided promising results regarding patient 
survival.1, 2 Currently, CRS combined with HIPEC is considered as a standard treatment for 
malignant peritoneal mesothelioma3, 5 and pseudomyxoma.3, 6 Good results and significant 
survival benefits after CRS and HIPEC were also shown for selected patients with peritoneal 
metastasis from colorectal cancer.7 However the survival benefit is achieved at the cost of 
increased morbidity and mortality due to an extensive surgery and intraoperative chemotherapy. 
The reported major complication rates after CRS and HIPEC range from 25% up to 60%, which 
is an important argument for many physicians against CRS/HIPEC.8, 9 To standardize the 
reporting of complications after CRS and HIPEC, the Common Terminology Criteria for Adverse 
Events version 3.0 (CTCAE) was proposed during the consensus conference in Milan in 2006.9 
This recommendation is not uniformly accepted. In contrast, the therapy-oriented Clavien-Dindo 
classification of surgical complications is widely used and validated in other fields of surgery.10-12 
Yet, the use of two different classification systems in the reporting of postoperative outcomes 
creates dilemma in interpretation and comparison postoperative outcomes in the field of 
CRS/HIPEC.  
We therefore designed this study to analyze postoperative complications after 
CRS/HIPEC. In a first step we reviewed the postoperative complications in our patients cohort 
after CRS/HIPEC.  In a further step, we compared the two classification systems CTCEA and 
Clavien-Dindo with regards to reproducibility, simplicity and accuracy. 
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Patients and methods  
Patients  
Complications were recorded in 147 consecutive patients, admitted with primary or 
secondary peritoneal malignancy. The complication grade determined according to the CTCAE 
and the Clavien-Dindo classification. Clavien-Dindo grades IIIb-IV and CTCAE grades III-IV 
were considered as ‘‘major’’ complication. The local ethical review board approved the study 
protocol (KEK-ZH-Nr. 2015-0269).  
Survey questionnaire and raters   
A questionnaire with randomly selected complications was designed. The severity grade 
of selected cases was defined after discussion by expert board. The raters were asked to define 
their level of certainty and the simplicity of the scores in a visual analog scale ranging from 0 to 
10. A separate field was provided to define the grade of complication and the duration of time 
spent to decide upon the complication grade. Fluency in English was prerequisite, thus the 
classifications were provided only in English.  
Fifty-four residents, 30 experienced attending surgeons and 28 medical oncologists were 
contacted to answer the questionnaire with a set of complications. The raters were randomized 
to evaluate the similar questionnaire with either the CTCAE or the Clavien-Dindo classification 
and received uniform introduction in the same way throughout the survey. Some surgeons had 
experience with the Clavien-Dindo classification and all medical oncologists had experienced 
with the CTCEA, since unfamiliarity with some of the grading systems was not mandatory for 
raters. No reimbursement was provided for participation. The questionnaire was submitted 
anonymously. Up to three reminders were sent to raters per e-mail or phone, if there was no 
response. Four study nurses trained in the Clavien-Dindo classification were contacted to 
evaluate the same questionnaire. Study nurses trained in CTCEA were not available for the 
survey.  
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Results 
Morbidity and mortality after CRS/HIPEC  
The study cohort includes 83 female and 64 male patients with a median age of 53 years. 
Peritoneal carcinomatosis of appendicular origin was the commonest, followed by colorectal 
cancer, mesothelioma, ovarian cancer and gastric cancer. Overall, 37 % (54/147) patients had 
at least one postoperative complication. The major complication rate was 8.1% according to the 
Clavien-Dindo classification (grades IIIb-IV). Grading of the same complications according to the 
CTCAE (grades III-IV) showed this rate at 25.1% of the patients and was significantly higher 
compared to Clavien-Dindo classification (8.1 vs. 25.1 %, p = 0.0001). Assessment of multiple 
complications per patient revealed totally 86 complications as a unit in 54 patients. Analysis of 
these 86 complications as a unit showed that intestinal complications, e.g., anastomotic 
insufficiency, fistulas or abscess 19.8% (17/86), pulmonary complications 19.8% (17/86) and 
ileus 15.1 (13/86) were most frequent one. 76% (65/86) of complications were graded as 
“minor” (less than grade IIIb according to Clavien-Dindo classification) and respectively could be 
managed without redo-surgery or admission to intensive care unit. The mortality rate was 2% 
(3/147). In one case the patient died due to postoperative bleeding secondary to a pancreas 
fistula, one patient developed fatal pulmonary failure in postoperative course and in third case a 
duodenal fistula with sepsis and a complicated course lead to death. 
Results of survey 
The response rate was among residents 74% (40/54), among seniors 70% (21/30) and 
among oncologists 75 % (21/28). All three groups assessed more correctly with Clavien-Dindo 
classification compared to the CTCAE classification: residents (62 vs. 32 %, p<0.001), surgeons 
(66 vs. 28 %, p<0.001) and oncologists (74 vs. 31 %, p<0.001). Of note higher rate of correct 
answers required less time to complete the questionnaire with Clavien-Dindo classification 
compared to CTCEA classification for residents (8 ± 4 min vs. 22 ± 10 min, p<0.001) as well as 
for surgeons (9 ± 5 vs. 19 ± 7, p = 0.006). The difference in time requirements for oncologists 
Page 8 of 12 
was statistically not significant (16 ± 11 vs. 23 ± 15, p = 0.4). Remarkably Clavien-Dindo 
classification showed also good inter-rater reliability among residents (0.67, p<0.001), surgeons 
(0.72, p<0.001) and oncologists (0.82, p<0.001), which was only moderate for CTCEA for all 
groups (residents: 0.34, p<0.001, surgeons: 0.45, p<0.001, oncologists: 0.39, p<0.001). 
Consistently, all three groups considered the Clavien-Dindo classification as more simple 
compared to the CTCAE classification: residents 7.1±2.2 vs. 4.5±2.3, p<0.001, surgeons 
8.4±0.8 vs. 4.1±2.9, p = 0.001 and oncologists 8 ± 1.5 vs. 5 ± 2.1, p = 0.03.  Subjective 
assessment of certainty was higher with Clavien-Dindo classification compared to CTCEA 
classification only for surgeons (8.4 ± 0.9 vs. 5 ± 2.7, p = 0.005). Residents (6.2 ± 1.9 vs. 5.4 ± 
1.5, p = 0.2) and oncologists (7.5 ± 1.2 vs. 6 ± 1.8, p = 0.1) showed similar certainty with both 
classifications.  
Four personnel trained in the Clavien-Dindo classification showed the highest rate of 
correct answers at 98 % (47/48).  
 
Conclusion 
In conclusion, we observed different interpretation of severity grades of postoperative 
complications after CRS/HIPEC between Clavien-Dindo and CTCEA classifications. Consistent 
reporting system of postoperative complications is urgently needed in the field of CRS/HIPEC. 
The optimal classification system for reporting complications after CRS/HIPEC should be 
defined by new consensus.    
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